General Effectiveness Report statistical analyses are criticized. Their analyses, which fostered the belief that the active treatments were indistinguishable, were compromised by an inappropriately stringent level of significance with regard to both heterogeneity of slope ad pairwise group differences. Once slope heterogeneity is detected, the Johnson-Neyman technique is more qpropriate than arbitrary sample subdivision. All of these tactics lowered power substantially.
INTRODUCTION
The National Institute of Mental Health Treatment of Depression Collaborative Research Program was a 16-week, multisite, randomized study that compared two psychotherapies, cognitive behavior therapy (CBT) and interpersonal psychotherapy (lPT), with placebo case management (PCM) and imipramine case management OCM) in the treatment of nonbipolar, nonpsychotic, depressed outpatients (Elkin et aI. 1985 (Elkin et aI. , 1989 .
Our reanalysis indicates a reasonable ordering for the treatments with medication superior to the psychotherapies and the psychotherapies somewhat superior to placebo. These effects are particularly marked among the more symptomatic and impaired patients. The lack of dosage by severity analyses renders the severity findings ambiguous.
Scientific and public health implications are discussed. [Neuropsychopharmacology 8:241-251, 1993J Four outcome measures were reported: Hamilton Depression Rating Scale (HDRS), the Global Assess ment Scale (GAS), the Beck Depression Inventory (BOI), and the Hopkins Symptom Check List-Total Score . The data were analyzed by univari ate 3 x 4 (sites x treatments) analyses of covariance (ANCOV A) for the scaled data and by chi square analy ses for treatment x recovery status data. The ANCOV As were followed by Bonferroni adjusted pairwise t tests and the chi square tests by Brunden adjusted pairwise comparisons. Tests for initial severity x treatment in teractions were also made. Three sets of analyses on overlapping samples were performed: (1) completer analysis on only those patients who completed the course of treatment; (2) endpoint analysis on patients who completed 3.5 weeks of treatment; and (3) end point analysis on all patients who entered the study.
Secondary analyses were conducted within less symp tomatic and less impaired subgroups as well as more symptomatic and more impaired subgroups.
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The standard reference treatment was ICM. The conclusions were startling. "Thus, there is no evidence in the major analyses that either of the psychothera pies was inferior to the standard reference treatment at termination of treatment on measures of depressive symptoms or general functioning. These statistical anal yses do not, of course, permit the inference that the psy chotherapies and the standard reference treatment were "equal" in effectiveness. However, since we had satis factory power in these analyses for detecting large effect size differences between pairs of treatments (in the to tal unstratifi.ed sample), it is unlikely that very large or important differences were missed." (Elkin et al. 1989) . The initial paragraph of their conclusions reaffirms this.
Despite the authors' disclaimer that they were not asserting that the treatments were "equal," they felt that nothing important had been missed. Therefore, as a practical matter one could as well choose one treatment as the other. Their statement fostered the interpreta tion that medication and psychotherapy were equiva lent for depression, as evidenced by a front page arti cle in the New York Times of May 14 , 19 86, entitled "Psychotherapy is as Good as Drug in Curing Depres sion, Study Finds." As recently as November 13, 19 89, The Wall Street Journal cited this study as follows, "Generally, the researchers cautiously conclude, there is no evidence that the psychotherapies are less effec tive than the antidepressant drug, but there was evi dence the psychotherapies were better than the placebo treatment." Elkin et al. (1989) reported only two signifi.cant treat ment fi.ndings; imipramine is superior to placebo on two different measures in two overlapping patient groups. Three "trends" were reported. It was reported twice that ICM was superior to PCM and, once that IPT was su perior to PCM. To sum up, in the undivided samples there was some evidence for ICM efficacy, minimal evi dence for IPT efficacy, no evidence for CBT efficacy, but no evidence of treatment differences. One signifi.cant site-by-treatment interaction was discounted since "there was no treatment effect on this variable." (Elkin et al. 19 89) .
These surprising, meager results led to controversy. Klein (1990) objected to four aspects of the analysis. These were: (1 ) an inappropriately stringent level of signifi.cance used in the necessary preliminary analy sis for heterogeneity of slope in the ANCOV A; (2) a lack of attention to initial severity once slope heterogeneity was detected; (3) the arbitrary, unnecessary, and strin gent signifi.cance level adjustments in the multiple treat ment comparisons; and (4) the arbitrary subdivision of the sample to explore severity effects, rather than using analyses that take advantage of slope heterogeneity and preserve the entire sample. Each of these tactics low ered power substantially, making it easier to miss real differences. We argue that real, clinically important, NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 fi.ndings were obscured by a veil of "statistical in signifi.cance" allowing the erroneous imputation of no important treatment differences.
Reanalysis Outline
We amplify their ANCOV A attending to the crucial is sue of heterogeneity of slope, thereby showing that many between treatment contrasts were obscured. We present statistically meaningful treatment comparisons, unreported by Elkin et al. , because of their unneces sary Bonferroni limitation, and both criticize and replace their "secondary analyses." We discuss multiple con trast control, attrition, dosage, comparison of IPT and CBT, and the procedural and scientifi.c implications of this reanalysis.
Analytic Strategy of Elkin et al.
Elkin et al. conducted ANCOV As on four measures; the HDRS, the GAS, the BDI, and the HSCL-90 .
"Marital status, which was signifi.cantly related to outcome, was not distributed evenly across treatment groups ... it was always used as a covariate in the ANCOV As. Pretreatment scores on the dependent vari able were also included as a covariate, except in those few instances on the HDRS and GAS in which there was signifi.cant (p < .0 5) heterogeneity of regression and the use of a pooled regression for the ANCOV A was not justifi.ed. In these instances, the ANCOVAs re ported used only marital status, and not pretreatment score, as a covariate." The overall sample was divided into three overlapping subsamples: the completer sarn pIe (n = 15 5); the endpoint 204 sample, which included all patients who received 3.5 weeks of treatment; and the endpoint 239 sample, which consisted of all patients who entered treatment. The ANCOV A used a last ob servation carried forward technique within each sub sample.
"To protect against inflation of the type I error rate associated with multiple comparisons, probability lev els for comparisons between pairs of treatments were adjusted for the total number of comparisons, by means of the Bonferroni t test ... an overall probability level of p < .10 was accepted for the F test between the 4 groups. However, for the crucial initial heterogeneity of slope analysis, the more stringent p value of .0 5 or less was required, this means that the probability level obtained must actually be < .017 to be considered signifi.cant at an adjusted alpha level < .10 .. . This ap proach left us with satisfactory statistical power (.81 to .9 5) to detect medium size effects in our primary ANCOV As" (Elkin et al. 19 89) .
Reanalysis
The NIMH recently released a public access tape con taining only the data that underlies published analyses.
Despite statements that the published data were ade quate to conduct alternative analyses (Hirschfeld 1990 it is rejected is called for. We need a method sensitive to possible slope diff erences so that inappropriate ANCOV As are not performed, and one that will use the information contained in slope differences if they are found.
We used the following strategy. First, an overall test for slope diff erences was performed. Alpha was set at .1 0. This is not as conservative as the authors cited sug gest but is better than testing at the .0 5 level. The initial overall tests used the same model as Elkin et al.; the four treatment groups and the post-and pretreatment scores of the variable being tested were included. The slope estimates from these analyses are the ones reported in Table 1 . If the null hypothesis was rejected, tests for pairwise slope diff erences were performed at were omitted. In this data set, the same decisions would have been made to pursue pairwise contrasts if instead of a = .1 0, we used the rule that the omnibus F had to be greater than one (see Table 2 ). That could be an alternative rule.
There is no way to simultaneously increase the power to detect real diff erences and to reduce the chances of falsely claiming to detect nonexisting differ ences, other than increasing the sample size. Given a fIxed sample size, one can only try to sensibly balance these aims. We believe that Elkin et al. used a strategy that made it unduly diffi cult to detect slope diff erences, resulting in the ANCOV A being used inappropriately and in losing valuable information about the differen tial effect of treatments for diff erent levels of initial pathology. The method used here allows us to detect treatment effects previously missed without incurring an unreasonable probability of type I error.
Reanalysis of Slope Heterogeneity
In only two analyses by Elkin et al., • Pairwise contrast signifIcant although overall F < 1.
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observed sample intersection will lie within the region of possible intersection. IeM versus peM on the GAS in the completer group.
Johnson-Neyman Analyses
The In no case is as much as 1% of the sample beyond the con&dence limit at the non pathologic end of the scale nor in the farther out subregion of a two-part region of possible intersection.
Since the con&dence limit at the less pathologic pole is always at or beyond the range of initial severity, there is never a real situation where one treatment is supe rior in the most pathologic range but treatment superi ority is reversed in the least pathologic range. At the conventional .05 level, ICM is superior to PCM on both the HDRS and the GAS, with similar cut points in the 204 and 239 groups. In the completer group, ICM is also superior to PCM on the HDRS at a point slightly higher along the severity dimension.
In the 204 group, ICM is superior to both IPT and CBT on the GAS. for both the 239 and 204 groups; IPT is superior to PCM on the HDRS in the 239 group and the GAS in the 204 group; lCM is superior to CBT on the BOI in the 204 and the completer groups; IPT is superior to CBT on the BOI for the 204 and the completer groups; and ICM is superior to PCM on the HDRS for the completer group; all using 95% limits.
Using 90% confIdence limits, there is a trend in the completer group for ICM to be superior to CBT on the HDRS and in the 239 group for IPT to be superior to PCM on the GAS. Elkin et al. found no signifIcant diff erence between II'I' and CBT in any major analysis or in their "second ary" split group analyses. Furthermore, they stated that the magnitude of the differences between these psy chotherapies is small even when IPT was signifIcantly diff erent from PCM but CBT was not. Surprisingly, on the BOI scores among the completers, CBT is signifI cantly inferior to IPT, which is repeated in the 204 group at a slightly greater level of severity. The BOI is the stan dard instrument for evaluation of CBT effects (see Fig   ure 4 ).
The two psychotherapies lay on either side ot the PCM slope so that their respective differences from PCM were not great. However, for slope, the p value for IPT versus PCM was .25 and for CBT versus PCM was .21. These two p values are at the outer limit of the val ues suggested by Hays as indicating possible heter ogeneity of slope. However, since the psychotherapies lay on opposite sides of the PCM slope, they differed sharply from each other.
If confmned in subsequent studies, this indicates that CBT is relatively inferior to IPT for patients with BOI scores greater than approximately 30, generally considered the boundary between moderate and severe depression.
Reanalysis of NIMH 247
If psychotherapy functions by antidemoralization, a psychotherapy that accentuated the positive and ig nored eliminating the negative would be most effective.
Perhaps for patients who score high on the BOI, the CBT focus upon rigid, dysfunctional attitudes produces a defeat experience. Interpersonal therapy, which fo cuses elsewhere, may have provided nonspecifIc sup port without direct confrontation.
Since efficacy differences between psychotherapies are rare, it is difficult not to be intrigued. However, the minimal differences from PCM make replication neces sary. The requirement of a minimal credible compari son condition (e.g., PCM) in psychotherapy evaluation is supported by this trial. Studies that lack this com parison are irretrievably ambiguous (Klein and Rabkin 
).
This analysis reveals meaningful differences be tween active treatments that were not detected in total group analyses by Elkin et al. Furthermore, this is not a secondary analysis, but derives directly from the same covariance analyses insensitively analyzed by the Elkin group. Responding to criticism, Elkin et al. performed "al ternative" analyses that were still vitiated by low power analysis for heterogeneity of slope. They concluded, "We did not find, as Dr. Klein seems to assume we would, an overall superiority of medication to psy chotherapy or both psychotherapies to placebo." (Elkin et al. 1990 ). However, our analyses, as reported in Ta bles 4 and 5, find just this. It is not correct that these analyses are secondary because the design did not include severity stratifIca tion. In fact, these data have already been analyzed for severity by including the initial score as a covariate. What makes their analyses secondary is not the lack of stratifIcation (especially since ANCOVA is usually more powerful than stratifIcation) but rather the post hoc arbitrary subdivision. Since prior to the study they had not suggested that a split at these points would be fruitful, one cannot logically exclude the possibility of post-hoc data massage. The lack of power is due to stratifying the data into only two groups, which ignores meaningful outcome variance within strata, and the re duced n for estimating means and variances.
Group Comparisons
By referring to these analyses as secondary, the authors denigrate their importance, thus emphasizing the lack of diff erence between treatments. Their prob lem, however, stems directly from the fact that their low power analyses had not detected heterogeneity of slope in the fIrst place. Once slope heterogeneity is de tected, the correct Johnson-Neyman approach reveals their "secondary" analyses to be superfluous and mis leading.
DISCUSSION

Multiple Contrast Control
Since the Bonferroni correction used in the analysis of Elkin et al. has been widely accepted, we wish to re- The chance that any one component will not fail is .95.
If the components fail independently, the chance that where one "has a £mite number of inferences of interest specibed prior to the study. If these inferences are un related in terms of their content or intended use (al though they may be statistically dependent) then they should be treated separately and not jointly. If a deci sion (or conclusion) is to be based on these inferences and its accuracy depends on some joint measure of er roneous statements in the given set of inferences, then the collection of inferences should be considered jointly as a family." 1£ one overall decision will be made on the basis of numerous group comparisons (and if any group com parison was falsely positive, the entire decision would beerroneous), then you should have stringent rules for multiple comparisons. But that is not the case when evaluating several treatments since no overall decision is required, but rather a number of individually meaningful pairwise contrasts.
Recent articles (Rothman 1990; Saville 1990 ) empha sized that multiple comparison "corrections" are un necessary and that even " F protection" results in incon sistent inferences. '1nconsistent" means that exactly the same contrast between two groups will sometimes be considered signmcant, and at other times insignifIcant, depending on the outcome of the other irrelevant groups in the trial.
Science progresses by constructive replication, which is particularly important in treatment evaluation. A well-attested treatment, such as IeM, may fail to show statistically signifIcant differences from peM (Klein and Davis 1969) . Such failures are usually at tnbutable to rnisselection of the appropriate patient popul ation, but at times poor treatment conduct, in ad eq uate dosage, poor power, bad luck, and/or mis evaluation are the culprits.
Requiring severe signifIcance levels is only appro priate for defmitive experiments that require no repli cation. In ou r still-maturing fIeld, plagued by samples of convenience, poor measures, attrition, and diffIcult to detect biases, this is never the case. Unadjusted p values for even slight trends should be presented, al lowing the reader the freedom to be either stringent or to follow his nose towards replication.
Good design acknowledges an unpredictably high 
Treatment Technique and Dosage
Since the medication course has never been published or anyone given access to it, one cannot be sure that the flexible dosage pharmacotherapy was well done.
It is quite possible that milder patients received ineffec tive, small doses, which could account for the lack of specifIc medication benefIt for the less symptomatic or impaired patients.
Such dose-by-severity analyses should have been It is also unfortunate that the data concerning the acceptability of the psychotherapeutic interventions are not available.
CONCLUSIONS
The paucity of fIndings in the original paper is largely due to unnecessarily stringent levels of signifIcance for both slope heterogeneity and group contrasts.
Elkin et al. concluded that the value of imipramine has been shown but the active treatments could not be distinguished. We correct this by indicating superiority of reM to the psychotherapies.
Our analyses also show some superiority of psy chotherapy to peM but the implications are not clear. Fawcett (1990) , who supervised the psychopharmacol ogy and case management approach stated that this was not free of strain and that some of the psychiatrists did not value their role and tended to cut short the sessions.
These clinicians were initially hired to become trainers but were shifted into a direct treatment role.
Fawcett's statement raises the question of compara tive treatment credibility. In evaluating a psychother apy, it must be compared with a credible treatment. If measured, these data have not been presented. If the major motor of psychotherapy is relief of demoraliza tion through credibility, as Frank has suggested, this is necessary (Klein and Rabkin 1984) . Klein, or anyone else who so wishes, to reinterpret the published data." However, these statements are incorrect since the regression slopes could not be calculated, despite our determination, until the release of the partial data tapes allowed alternative analyses. If it is difficult for an arti cle to present the data necessary for alternative analy ses, the data (or the more complex summary statistics) underlying the presented analyses should, ideally, be available on request. Means and sample sizes for each subgroup as well as the pooled within groups disper sion matrix for all variables in the analysis would most conveniently allow readers to reproduce the investiga tors' tests for adjusted mean differences. In addition, individual dispersion matrices for each group would be needed to check tests for slope differences and homogeneity of variance between groups and to per form Johnson-Neyman analyses.
There is a problem in intellectual property rights.
Those who developed the ideas and did the work have a legitimate interest in receiving credit for the study, analyzing the data, and publishing the results. It is not unusual for there to be several years spent at data anal ysis and write up of a complex study. To release data prior to the completion of this task may result in others, rather than the original group, receiving the credit for making discoveries.
On the other hand, both the scientific and lay pub lics have an interest in rapid, thoughtful, data analysis so that public health implications as well as heuristic inferences can be properly considered. This should be a matter of widespread public interest, but has not been openly discussed with the scientific or lay community.
Important public health issues often require widespread multisite collaborative efforts. The mechanism for achieving this goal is properly a subject for discussion by those affected by these procedures, including the NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 general public. It would be natural for NIMH to span· sor a series of meetings to attempt to deal with these complex issues.
